Epitomee Medical specializes in the development of innovative ingestible therapeutic devices designed to address chronic diseases through targeted therapies along the gastrointestinal (GI) tract. Their platform technology is engineered to provide mechanosensory stimulation, which can be adapted for various applications, including weight management and biologics delivery. The devices are designed with the anatomy of the GI tract in mind, allowing for controlled activation and targeted deployment in specific regions such as the stomach, duodenum, and small intestine. This adaptability ensures that the therapies can be delivered effectively and comfortably, enhancing patient experience and treatment outcomes.

The ingestible devices are self-administered and come in a swallowable capsule format, which allows for ease of use. They are engineered for transient activity, meaning they interact with the GI tract for a set duration before dissolving and being naturally expelled from the body. Epitomee Medical collaborates with multinational industry leaders to commercialize these advanced therapies, aiming to significantly improve the quality of life for patients suffering from chronic conditions. Through these partnerships, the company seeks to expand the applications of their technology and bring innovative solutions to the healthcare market.

Israel

Epitomee is a medical devices company developing ingestible devices to tackle some of today's most prevalent chronic diseases at their core with a self-managed, safe and effective way. Epitomee  has developed,  and is commercializing drug-free self-administered capsules, aimed to prevent diabetes and address overweight & obesity comorbidities by promoting weight loss and establishing a healthier lifestyle.

Tarshish industrial park Street, Caesarea, Haifa District, IL, 3079563

Epitomee Medical

Company Details